These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30679780)

  • 1. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
    Evans TRJ; Dean E; Molife LR; Lopez J; Ranson M; El-Khouly F; Zubairi I; Savulsky C; Reyderman L; Jia Y; Sweeting L; Greystoke A; Barriuso J; Kristeleit R
    Br J Cancer; 2019 Feb; 120(4):379-386. PubMed ID: 30679780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
    Twelves C; Anthoney A; Savulsky CI; Guo M; Reyderman L; Cresti N; Semiglazov V; Timcheva C; Zubairi I; Morrison R; Plummer R; Evans TRJ
    Br J Cancer; 2019 Mar; 120(6):579-586. PubMed ID: 30783204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
    Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin mesylate in patients with refractory cancers: a Phase I study.
    Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
    Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
    Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
    Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
    Koczywas M; Frankel PH; Synold TW; Lenz HJ; Mortimer JE; El-Khoueiry AB; Gandara DR; Cristea MC; Chung VM; Lim D; Reckamp KL; Lau DH; Doyle LA; Ruel C; Carroll MI; Newman EM
    Br J Cancer; 2014 Dec; 111(12):2268-74. PubMed ID: 25349975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
    Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
    Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
    Sakiyama T; Tsurutani J; Iwasa T; Kawakami H; Nonagase Y; Yoshida T; Tanaka K; Fujisaka Y; Kurata T; Komoike Y; Nishio K; Nakagawa K
    Br J Cancer; 2015 Mar; 112(5):819-24. PubMed ID: 25654665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.
    Ida H; Shimizu T; Nishino M; Nakamura Y; Yazaki S; Katsuya Y; Sato J; Koyama T; Iwasa S; Sudo K; Kondo S; Yonemori K; Shitara K; Shiono S; Matsuoka D; Yasuda K; Otake Y; Suzuki T; Takase T; Takashima S; Yamaguchi K; Semba T; Yamamoto N
    Cancer Res Commun; 2023 Jul; 3(7):1189-1199. PubMed ID: 37435605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.
    Goel S; Swami U; Kumar K; Dittrich C; Reyderman L; Jain M; Aisner J; Song J; Petrylak DP
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):567-578. PubMed ID: 31190276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
    Roviello G; Milani M; Gobbi A; Cappelletti MR; Zanotti L; Senti C; Bottini A; Strina C; Sigala S; Generali D
    Clin Breast Cancer; 2016 Jun; 16(3):e57-9. PubMed ID: 26943987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
    Lee JS; Yost SE; Blanchard S; Schmolze D; Yin HH; Pillai R; Robinson K; Tang A; Martinez N; Portnow J; Wen W; Yim JH; Brauer HA; Ren Y; Luu T; Mortimer J; Yuan Y
    Breast Cancer Res; 2019 Nov; 21(1):119. PubMed ID: 31703728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
    Masuda N; Ono M; Mukohara T; Yasojima H; Shimoi T; Kobayashi K; Harano K; Mizutani M; Tanioka M; Takahashi S; Kogawa T; Suzuki T; Okumura S; Takase T; Nagai R; Semba T; Zhao ZM; Ren M; Yonemori K
    Eur J Cancer; 2022 Jun; 168():108-118. PubMed ID: 35500404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
    Devriese LA; Witteveen PO; Marchetti S; Mergui-Roelvink M; Reyderman L; Wanders J; Jenner A; Edwards G; Beijnen JH; Voest EE; Schellens JH
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):823-32. PubMed ID: 23010853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
    Sato J; Shimizu T; Koyama T; Iwasa S; Shimomura A; Kondo S; Kitano S; Yonemori K; Fujiwara Y; Tamura K; Suzuki T; Takase T; Nagai R; Yamaguchi K; Semba T; Zhao ZM; Ren M; Yamamoto N
    Clin Cancer Res; 2022 May; 28(9):1783-1791. PubMed ID: 35180771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
    Hattori M; Ishiguro H; Masuda N; Yoshimura A; Ohtani S; Yasojima H; Morita S; Ohno S; Iwata H
    Breast Cancer; 2018 Jan; 25(1):108-117. PubMed ID: 28861862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
    Reda M; Macaire P; Bellio H; Uwer L; Ilie S; Lorgis V; Hennequin A; Ladoire S; Rederstorff E; Fumoleau P; Isambert N; Bonnin N; You B; Freyer G; Desmoulins I; Schmitt A
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):197-208. PubMed ID: 34997290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
    Devriese LA; Witteveen PE; Wanders J; Law K; Edwards G; Reyderman L; Copalu W; Peng F; Marchetti S; Beijnen JH; Huitema AD; Voest EE; Schellens JH
    Br J Clin Pharmacol; 2013 Feb; 75(2):507-15. PubMed ID: 22803519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.